How Tirzepatide Works
Tirzepatide activates two receptors simultaneously: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). This dual mechanism reduces appetite, slows gastric emptying, improves insulin sensitivity, and may have additional effects on fat metabolism compared to GLP-1-only agents.
Like semaglutide, tirzepatide is administered as a once-weekly subcutaneous injection and is titrated gradually over several months. The dual agonist mechanism is believed to contribute to its stronger effect on body weight observed in clinical trials.
The SURMOUNT-1 trial showed average weight loss of up to 22.5% of body weight over 72 weeks in adults with obesity. Individual results vary and are not guaranteed.
Who It's For
A licensed provider will evaluate your complete health history before recommending tirzepatide. In general, it may be considered for adults who:
✓
Have a BMI of 30 or higher, or a BMI of 27 or higher with a weight-related condition
✓
Have not achieved adequate results through diet and exercise alone
✓
Do not have contraindicated conditions (including personal or family history of medullary thyroid carcinoma or MEN 2)
✓
Are not pregnant or planning to become pregnant during treatment
Only a licensed healthcare provider can determine whether tirzepatide is appropriate for you. This is not medical advice.
How the Program Works
01
Complete Your Online Evaluation
Answer questions about your health history, current medications, and weight loss goals through our clinical partner's HIPAA-compliant portal.
02
Provider Review
A licensed healthcare professional independently reviews your information and determines whether tirzepatide is medically appropriate for you.
03
Prescription & Pharmacy Fulfillment
If approved, your prescription is filled by a licensed US-based 503A compounding pharmacy or FDA-registered 503B outsourcing facility and shipped directly to you.
04
Ongoing Support
Your provider monitors your progress, adjusts your dose as needed, and is available through your patient portal for questions and check-ins.
Compounded vs. Brand-Name Tirzepatide
Brand-name
Brand-name tirzepatide products (Mounjaro® for diabetes and Zepbound® for weight management) are FDA-approved drugs manufactured under strict FDA oversight.
Compounded
Compounded tirzepatide is prepared by state-licensed 503A compounding pharmacies or FDA-registered 503B outsourcing facilities. Compounded tirzepatide is not FDA-approved — it has not been evaluated by the FDA for safety, efficacy, or quality in the same way brand-name drugs have.
LeoCore Health's clinical partner works exclusively with licensed US-based compounding pharmacies and FDA-registered outsourcing facilities. Patients should discuss the specific medication being prescribed with their licensed provider.
Ready to Take the Next Step?
Start with a confidential online evaluation. A licensed provider will review your health history and goals to determine whether treatment may be appropriate for you.
Individual results may vary. Treatment is subject to provider evaluation and approval. LeoCore Health does not provide medical care directly.
Side Effects and Safety
Tirzepatide has a similar side effect profile to semaglutide, with gastrointestinal effects being most common during dose escalation.
Nausea
The most common side effect, particularly in the first few weeks. Usually improves as the body adjusts.
Vomiting and diarrhea
Less common than nausea. Typically transient and manageable with dietary adjustments.
Constipation
Occurs in some patients. Increased fiber and hydration are typically recommended.
Decreased appetite
A primary mechanism of action. Some patients may need to be mindful of maintaining adequate nutrition.
Tirzepatide carries a boxed warning for patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Serious adverse events including pancreatitis and gallbladder disease are rare but possible. Seek immediate medical attention for severe abdominal pain or signs of an allergic reaction.
Read the full weight loss guide →
Frequently Asked Questions
Is tirzepatide stronger than semaglutide?
Clinical trials have shown tirzepatide to produce greater average weight loss than semaglutide in head-to-head comparisons, likely due to its dual GIP/GLP-1 mechanism. However, individual responses vary, and a licensed provider will help determine which medication may be more appropriate based on your health history.
Is tirzepatide the same as Mounjaro or Zepbound?
Tirzepatide is the active ingredient in both Mounjaro® (approved for type 2 diabetes) and Zepbound® (approved for weight management). Compounded tirzepatide contains the same active ingredient but is not FDA-approved. Your provider will discuss which form is being prescribed.
Do I need a prescription?
Yes. Tirzepatide is a prescription medication. A licensed provider must evaluate your health history and determine whether it is medically appropriate for you before a prescription can be issued.
How long does it take to see results?
Individual responses vary. Clinically meaningful weight changes are typically observed over three to six months of treatment. Results are not guaranteed.
Is tirzepatide covered by insurance?
Coverage varies widely. Many plans do not cover tirzepatide for weight management specifically. See our pricing page for transparent starting prices for compounded tirzepatide programs.
How is tirzepatide administered?
Tirzepatide is administered as a once-weekly subcutaneous injection, typically in the abdomen, thigh, or upper arm. Your provider will give you instructions on self-injection technique.
RELATED